CANCER THERAPEUTICS PIPELINE:
miR-21 based therapeutics for lung cancer in discovery and optimization phase.
> Results showed that miR-21 is commonly upregulated in NSCLC cell lines and tissues with important functional consequences
> anti-miR-21 significantly inhibits growth, migration and invasion, and reverse chemo- or radioresistance of NSCLC cells
miR-484 based therapeutics for ovarian cancer in discovery and optimization phase
> miR-484 revealed that the sensitive phenotype is caused by a modulation of tumor vasculature through the regulation of the VEGFB and VEGFR2 pathways
> multicenter cohort demonstrated that mir 484 was involved in the control of ovarian tumor angiogenesis
miR-17 cluster (6 miRs) based therapeutics for colon cancer in discovery phase.
> miR-17-5p inhibitor showed growth inhibition, spontaneous apoptosis, higher caspase-3 activation, and increased chemosensitivity to gemcitabine
> Among one of the most recognized in multiple types of cancers
undisclosed miR-based therapeutics for prostate cancer in early discovery phase.
> Identifying potential targets in collaboration with Carlo Croce’s Lab